Amphastar Pharmaceuticals (AMPH) DCF: History & Chart

Amphastar Pharmaceuticals, Inc.(AMPH)

Drug Manufacturers - Specialty & Generic · Rancho Cucamonga, CA

$25.13-0.24 (-0.95%)

Delayed quote: Oct 6, 2026, 10:35 AM EDT

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Rancho Cucamonga, CA

1,976 employees

www.amphastar.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Yongfeng Zhang

View full financials

Amphastar Pharmaceuticals, Inc. (AMPH) DCF Valuation

Price is BELOW the estimated range

$50.02

$97.76

Model scenario range

$25.13

Today's price

TGM's two-stage DCF values Amphastar Pharmaceuticals, Inc. (AMPH) between $50.02 and $97.76 depending on assumptions, with a base case of $69.24. Growth is taken from the company's own record (5-year revenue CAGR (FCF growth too volatile to use)), fading to 2.5% long-run; the discount rate (8.7%) reflects its beta.

What would today's price require?

Growth the price assumes-5.8%/yr

Actual FCF growth, last 5 years+23.9%/yr

$25.13 is justified only if free cash flow grows about -5.8% a year (fading to 2.5% long-run) at a 8.7% required return — slower than the company has actually grown.

Scenario	FCF growth (fading to 2.5%)	Discount	Value / share
Conservative	10.7%/yr	9.7%	$50.02
Base case	13.7%/yr	8.7%	$69.24
Optimistic	16.7%/yr	7.7%	$97.76
Third-party model estimate (FMP)	independent reference · retrieved Oct 6, 2026 · assumptions not provided		$82.51

The FMP figure is a third-party point estimate. Its cash-flow forecast, discount rate, terminal growth, and valuation date are not included in the stored response, so TGMCharts presents it only as a reference—not as an intrinsic-value conclusion or price target.

Price|PE Ratio|FCF Yield|All Metrics

Current Price

$25.13

Market-Implied Growth

-5.8%/yr

vs +23.9% 5Y actual

Model Scenario Range

$50.02 – $97.76

model output — not a price target

AMPH DCF Fair Value Calculator

Edit the assumptions to see how they change the estimated fair value. Opens seeded with TGM's data-driven base case for AMPH (growth from its own 5-year record, discount from its beta), so the sandbox starts where the scenarios above leave off. Illustrative model — not investment advice.

FCF Growth Rate13.7%/yr

Historical FCF CAGR: 3Y 15.0% · 5Y 23.9% · 10Y 28.6%

Discount Rate (WACC)8.7%

Terminal Growth2.5%

Projection Years10yr

Base inputs: FCF $133.3M · 0.04B shares · net debt $440.1M

Estimated Fair Value

$69.24

+175.5% vs $25.13

Current price$25.13

Third-party model estimate (FMP)$82.51

Sensitivity — fair value by discount rate × terminal growth

How the estimated fair value shifts with the discount rate (WACC) and terminal growth, holding your 13.7%/yr FCF growth and 10-year horizon fixed. Green = above today's $25.13; red = below. Your current case is outlined.

WACC ↓ / Terminal →	1.50%	2.00%	2.50%	3.00%	3.50%
6.7%	$88.81	$97.95	$109	$124	$142
7.7%	$72.02	$78.11	$85.37	$94.16	$105
8.7%	$59.93	$64.24	$69.24	$75.11	$82.09
9.7%	$50.82	$54.00	$57.62	$61.77	$66.58
10.7%	$43.72	$46.14	$48.86	$51.92	$55.41